CRISPR RNA Editing Turns “Invisible” Prostate Tumors into Targets for Immunotherapy

Prostate cancer usually responds poorly to immunotherapy because the tumor hides from the immune system, earning the label of an “immune‑cold” cancer. A new RNA‑targeted CRISPR technology developed at Duke University School of Medicine and collaborating institutions re‑exposes these tumors to immune attack in mice by restoring a key protein complex on cancer cells that T cells need in order to recognize and kill them.

A key part of this invisibility trick is a structure on the cell surface called MHC class I, an “ID badge” that shows protein fragments to T cells. When MHC class I is present, T cells can scan cells and spot those that look abnormal; when it is missing or reduced, cancer cells are much harder to find. Many prostate tumors lower MHC class I and slip past immune surveillance, staying “cold” and responding poorly to immunotherapy.

A new study in Nature Biomedical Engineering reports an RNA‑targeted CRISPR tool that tackles this visibility problem and makes prostate tumors easier for T cells to see, at least in mice.

In many prostate cancers, the mRNA (messenger RNA) for a protein called SPSB1 has an abnormally shortened tail, the 3′ untranslated region (3′UTR). This shortening removes normal control signals, so the cell makes too much SPSB1, which then helps tag MHC class I for destruction. The result is high SPSB1, low MHC class I, and tumors that can ignore T cells and checkpoint drugs.

The new platform, 3′UTR CRISPR/dCas13 Engineering System (3′UTRCES), uses a modified Cas13 enzyme that binds RNA without cutting it. Guided by a short RNA, dCas13 blocks the site where SPSB1 mRNA is normally shortened, forcing the cell to rebuild a longer 3′UTR with its natural control elements. When SPSB1 mRNA regains its full tail, SPSB1 protein falls and MHC class I returns to the tumor cell surface.

All of this happens at the RNA level; the DNA stays untouched, so there is no permanent genome editing. That makes the approach more reversible in principle and fits a broader trend in biotechnology toward editing cellular “messages” rather than rewriting the underlying code.

To test whether repairing these ID badges truly changes immunity, the team packaged 3′UTRCES into lipid nanoparticles, similar to those used in mRNA vaccines, and delivered it to mice with prostate tumors. In these models, LNP‑3′UTRCES reversed SPSB1 mRNA shortening, lowered SPSB1 protein, restored MHC class I, and increased the number and activity of CD8 T cells inside tumors.

The most striking result came when this RNA tool was combined with immune checkpoint therapy. Tumors that had resisted checkpoint inhibitors became sensitive after 3′UTRCES, showing better tumor control than either treatment alone. In simple terms, fixing antigen presentation turned an immune‑cold prostate cancer into a hotter, more inflamed tumor that finally responded to existing immunotherapy.

Source.